LabGenius Therapeutics ("LabGenius") is a drug discovery company pioneering the discovery of next-generation therapeutic antibodies. The company’s discovery platform, EVA™, integrates several cutting-edge technologies drawn from the fields of artificial intelligence, robotic automation and synthetic biology. While EVA™ is both modality and format-agnostic, LabGenius' internal pipeline is focussed on the development of selectivity-enhanced antibodies for the treatment of solid tumours. The company's novel approach is delivering a pipeline of antibody therapeutics with best-in-class killing profiles.
Company Details
- Employees
- 66
- Founded
- -
- Address
- 100 Drummond Road, Bermondsey, London,uk Se16 4dg,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.labgeniustx.com
- Keywords
- Medical, Health, DNA Libraries.
- HQ
- London, UK
Labgenius Therapeutics Questions
Labgenius Therapeutics's website is http://www.labgeniustx.com
Labgenius Therapeutics's LinkedIn profile is https://uk.linkedin.com/company/labgeniustx
Labgenius Therapeutics has
66 employees.
View email and phone details for 66
employees at Labgenius Therapeutics.
Labgenius Therapeutics's industry is
Biotechnology Research
Labgenius Therapeutics's top competitors are
Healx,
Exscientia,
Isomorphic Labs,
Basecamp Research,
Bactobio,
Uncommon,
Multus,
Synthace,
Hoxton Farms,
Benevolentai.
Labgenius Therapeutics's categories are Biotechnology Research
Labgenius Therapeutics's founding year is 2012
